Phase 1 Trial: SX-682 Combination with Standard of Care in Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute is evaluating SX-682—a CXCR1/2 inhibitor—in combination with carfilzomib, daratumumab-hyaluronidase, and dexamethasone for patients with secretory multiple myeloma that has relapsed or is refractory after at least one prior treatment. This phase 1 trial will assess the safety, tolerability, and preliminary efficacy of this regimen administered in 28-day cycles, with comprehensive monitoring including blood sampling, bone marrow aspirates, cardiac imaging, and advanced radiologic assessments.